Explore Recent News
Epredia Expands Anatomical Pathology Business in Europe with Acquisition of Microm Microtech France and Laurypath
September 5, 2022
Epredia, a global leader in precision cancer diagnostics, today announced that its parent company PHC Holdings Corporation [TSE 6523] has acquired anatomical pathology suppliers Microm Microtech France (MMFrance) and Laurypath in a strategic expansion of Epredia’s presence in Europe.
MMFrance and Laurypath, both founded in 1987 in Lyon, France, manufacture and supply anatomical pathology products and provide services for laboratories throughout France, offering high levels of technical support and a local supply of reagents and other consumables used in cancer diagnostics. Both companies will now operate as fully owned subsidiaries of PHC Holdings Corporation (PHC Group)…Read more
Epredia Launches Laser Cassette Printers Designed to Improve Sample Tracking and Laboratory Efficiency
August 30, 2022
Epredia, a global leader in precision cancer diagnostics, today announced that it has launched U.S. sales of two state-of-the-art printers used in laboratories to identify and track tissue samples. The NOVA and VEGA laser cassette printers are designed for anatomical pathology laboratories to improve both patient sample tracking and efficiency. The printers are manufactured by Fa-Tech Diagnostics Europe, BV, which Epredia acquired in 2021.
The NOVA and VEGA printers offer high-resolution, 600-dpi, laser printing that enables laboratories to include more identifying information directly on the cassettes that contain the tissue or bone samples being tested. This technology can embed up to 100 characters on each cassette, compared to 50 characters with older thermal transfer and ink jet technologies. This ability to print more detailed identifying information for each sample enhances the laboratory’s ability to effectively track samples throughout the diagnostics workflow…Read more
Aiforia Announces Closing of €17.5M Series B Funding Round
September 16, 2021
Aiforia, a software company providing AI-based solutions for clinical diagnostics and preclinical analysis to enable pathologists to translate medical images into diagnoses and discoveries with more efficiency and precision, announced today the completion of a €17.5M Series B funding round. The funding round is led by Epredia's UK entity, a subsidiary of PHC Holdings Corporation.
The funding helps accelerate the development and commercialization of Aiforia’s portfolio of clinical tools for AI-assisted support in the diagnosis of some of the world’s most prevalent diseases like breast and lung cancer — Aiforia intends to launch CE-IVD marked clinical tools for both diseases this year…Read more
Announcement of Approval for Listing of Shares of PHC Holdings Corporation on the Tokyo Stock Exchange
September 7, 2021
PHC Holdings Corporation (headquarters: Minato-ku, Tokyo, Japan, President & CEO: John Marotta) has today announced the approval by Tokyo Stock Exchange, Inc. (the “TSE”) for the listing of the shares of its common stock (the “shares”) on the First Section of TSE. The scheduled date for the listing of the shares is Thursday October 14, 2021, on or after which date the shares will be available for trading on the TSE*…Read more
This document is a press release prepared for the sole purpose of public announcement and is not prepared for the purpose of soliciting investment or engaging in any other similar activities thereto, whether within or outside Japan. In the event of making an investment in Japan, please carefully review the prospectus (including any amendments thereto) prepared by us and make an independent investment decision.
In addition, this press release is not an offer of securities for sale in the United States. The shares may not be offered or sold in the United States absent registration or an exemption from requirement. If any public offering of the shares is made in the United States, it will be by means of a prospectus that may be obtained from us or the selling shareholders and that will contain detailed information about us and our management, as well as our financial statements.
Epredia and Aiforia announce partnership for global distribution of AI-powered pathology software
June 21, 2021
Epredia, a global leader in precision cancer diagnostics, and Aiforia, a medical software company providing Artificial Intelligence (AI) based solutions for image analysis in pathology, have announced today that they have entered into a commercial distribution agreement for Aiforia’s comprehensive portfolio of workflow enhancing solutions which enable pathologists to harness the power of deep learning AI for image analysis.
Under the terms of this agreement, Epredia has been appointed as a global distribution partner for Aiforia’s portfolio of preclinical and clinical pathology tools, including segment exclusivity for distribution in Japan, Germany, UK, Italy, Spain, Sweden, Norway, Denmark, Iceland, France and the USA. From Summer 2021, Epredia will begin to commercialize the Aiforia portfolio of AI solutions. These solutions will be available as part of Epredia’s comprehensive digital pathology portfolio that already features the best-in-class CE-marked 3DHistech P1000 WSI scanner*…Read more
* Regulatory requirements for the 3DHistech P1000 scanner and Aiforia's pathology solutions vary by country, please consult with your commercial partner to confirm the availability and approved use of the scanner and Aiforia's pathology solutions in your country.
Epredia invests in Aiforia, a software company providing AI-based solutions for clinical and preclinical image analysis in pathology
June 3, 2021
Aiforia, a software company providing AI-based solutions for clinical and preclinical image analysis in pathology, announced today the closing of the first €12.6M tranche of their Series B round. The funding round has the potential to reach €25.2M if investors exercise the optional second tranche
The funding round is led by Epredia’s UK entity, a subsidiary of PHC Holdings Corporation. Investors also include Aktia Nordic Micro Cap and existing shareholders. KPMG acted as a financial advisor to Aiforia in the successful Series B round…Read more
Epredia and Paige announce global commercial distribution agreement for digital pathology software
March 17, 2021
Epredia, a global leader in precision cancer diagnostics, and Paige, a global leader in AI-based diagnostic software in pathology, have announced today that they have entered into a commercial distribution agreement for Paige’s comprehensive portfolio of diagnostic software solutions.
Under the terms of this agreement, Epredia has been appointed as a global distribution partner of the entire Paige portfolio of imaging diagnostic solutions. In addition, Epredia will have exclusive distribution rights in Japan. In the second quarter of 2021, Epredia will begin to commercialize the Paige solutions alongside existing Epredia products in the United States and major European Countries, further strengthening its comprehensive digital pathology portfolio that already includes the best-in-class CE-marked 3DHISTECH P1000 scanner*…Read more
* Regulatory requirements for the 3DHistech P1000 scanner vary by country, please consult with your commercial partner to confirm the approved use of the scanner in your country.
Epredia and Lunaphore announce commercial agreement for exclusive distribution of LabSat® Research
June 15, 2020
Epredia, a global leader in precision cancer diagnostics and tissue diagnostics, and Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, have announced today that they have entered into a distribution agreement. This follows the announcement of a strategic investment in Lunaphore by PHC Holdings Corporation, the parent company of Epredia, which was announced on February 6, 2020.
Under the terms of this agreement, Epredia have been appointed the exclusive distributor of the LabSat® Research platform in the US, UK and Germany, where Epredia will start to distribute the product in July 2020, as well as Japan, where commercialization will begin in 2021…Read more